New drug duo aims to shrink breast tumors before surgery
NCT ID NCT02562118
Summary
This study is testing whether adding a drug called lenvatinib to standard hormone therapy (letrozole) can better shrink breast tumors before surgery. It involves post-menopausal women with newly diagnosed, hormone receptor-positive breast cancer. The research first aims to find a safe dose of the combination, then measure how well it reduces tumor size compared to historical data on letrozole alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore, 119228, Singapore
Conditions
Explore the condition pages connected to this study.